TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
TEVA PHARMACEUTICAL INDUSTRIES LTD
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$41.31−0.19 (-0.46%)
Close on Oct 19, 2026
- Market cap
- $48.13B
- P/E (TTM)
- 68.9
- Dividend yield
- –
TEVA PHARMACEUTICAL INDUSTRIES LTD revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States [Member] | $9.19B | $8.03B | $7.73B | $7.00B | – | – | – | – | – | – | 53.2% | +14.3% |
| Europe [Member] | $5.04B | $5.10B | $4.84B | $4.53B | $4.89B | $4.76B | $4.80B | $5.19B | $5.47B | $4.97B | 29.2% | -1.2% |
| International Markets [Member] | $2.16B | $2.46B | $2.35B | $2.35B | $2.03B | $2.15B | $2.25B | $2.42B | $2.86B | $4.02B | 12.5% | -12.2% |
| Other Activities [Member] | $870.00M | $944.00M | $926.00M | $1.05B | $1.15B | $1.30B | $1.30B | $1.37B | $1.38B | $1.14B | 5.0% | -7.8% |
| Generics [Member] | – | – | – | – | – | – | – | – | $12.26B | $11.99B | – | – |
| Specialty [Member] | – | – | – | – | – | – | – | – | $7.91B | $8.67B | – | – |
| North America [Member] | – | – | $8.12B | $7.45B | $7.81B | $8.45B | $8.54B | $9.30B | $12.14B | $11.78B | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Corporate Segment [Member] | $5.00B | $4.31B | $4.34B | $3.97B | $4.25B | $4.23B | $4.03B | $4.61B | $6.08B | $6.84B | +15.9% |
| United States [Member] | $3.36B | $2.30B | $2.39B | $1.93B | – | – | – | – | – | – | +46.2% |
| Europe [Member] | $1.30B | $1.58B | $1.48B | $1.50B | $1.49B | $1.33B | $1.32B | $1.27B | $1.03B | $667.00M | -17.3% |
| International Markets [Member] | $336.00M | $440.00M | $465.00M | $538.00M | $529.00M | $474.00M | $464.00M | $498.00M | $426.00M | $636.00M | -23.6% |
| Other Segments [Member] | -$90.00M | $18.00M | $24.00M | $172.00M | $154.00M | $163.00M | $108.00M | $115.00M | -$6.00M | $8.00M | -600.0% |
| Generics [Member] | – | – | – | – | – | – | – | – | $2.83B | $3.31B | – |
| Specialty [Member] | – | – | – | – | – | – | – | – | $4.33B | $4.66B | – |
| Segments and Other Activities [Member] | – | – | $4.36B | $4.14B | $4.40B | $4.39B | $4.14B | $4.72B | $6.07B | $6.85B | – |
| North America [Member] | – | – | $2.40B | $1.99B | $2.22B | $2.42B | $2.25B | $2.84B | $4.62B | $5.54B | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sale of Goods [Member] | $14.61B | $14.05B | $12.98B | $12.77B | $13.83B | $14.35B | $14.51B | $15.88B | $19.26B | $19.99B | 84.6% | +4.0% |
| Distribution [Member] | $1.55B | $1.58B | $1.62B | $1.52B | $1.39B | $1.50B | $1.51B | $1.37B | $1.38B | $963.00M | 9.0% | -1.6% |
| Licensing Arrangements [Member] | $678.00M | $173.00M | $681.00M | $212.00M | $160.00M | $129.00M | $147.00M | $165.00M | $327.00M | $314.00M | 3.9% | +291.9% |
| Other [Member] | $423.00M | $745.00M | $570.00M | $428.00M | $500.00M | $680.00M | $716.00M | $852.00M | $886.00M | $637.00M | 2.5% | -43.2% |
| Generics [Member] | – | – | – | – | – | – | – | – | $12.26B | $11.99B | – | – |
| Branded [Member] | – | – | – | – | – | – | – | – | $7.91B | $8.67B | – | – |
| Other [Member] | – | – | – | – | – | – | – | – | $2.21B | $1.24B | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $9.19B | $8.03B | $7.73B | $7.00B | – | – | – | – | – | – | 53.2% | +14.3% |
| Europe [Member] | $5.04B | $5.10B | $4.84B | $4.53B | $4.89B | $4.76B | $4.80B | $5.19B | $5.47B | $4.97B | 29.2% | -1.2% |
| North America [Member] | – | – | $8.12B | $7.45B | $7.81B | $8.45B | $8.54B | $9.30B | $12.14B | $11.78B | – | – |
From the segment and revenue-disaggregation notes of Teva Pharmaceutical Industries's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.